

February 10, 2011

To whom it may concern:

Company Name : TOHO HOLDINGS CO., LTD.
Representative : Norio Hamada /
President and Representative Director
(Securities Code: 8129 / First Section of Tokyo Stock Exchange)
Contact : Katsuya Kato, Corporate Officer and
General Manager of Corporate Communications Office
and Corporate Planning Office
(TEL: 03-5259-9520)

Notice of the Integration of Dispensing Pharmacy Business in Niigata Prefecture and Hokuriku Area

TOHO HOLDINGS CO., LTD. is pleased to announce that the meeting of its Board of Directors held today (February 10, 2011), resolved details of the business reorganization of the dispensing pharmacy business in Niigata Prefecture and Hokuriku area. The details are as follows.

1. Purpose of the Business Reorganization

The Kyoso Mirai Group, with TOHO HOLDINGS as its core company, is a corporate group engaged in the distribution of pharmaceutical and other medical products. It has been working toward maximizing its group synergy through the active use of the managerial resources of all member companies under the group slogan, "Total Commitment to Good Health."

The Group has adopted a business management and control system under which the pharmaceutical wholesaling and the dispensing pharmacy businesses are centered on TOHO PHARMACEUTICAL CO., LTD., a wholly owned subsidiary of TOHO HOLDINGS (hereinafter "Toho Pharmaceutical"), and PharmaCluster Co., Ltd., another wholly owned subsidiary of the Company (hereinafter "PharmaCluster"), respectively. The Company today decided to reorganize the dispensing pharmacy businesses in Niigata Prefecture and Hokuriku area, with the aim of optimizing group-wide managerial resources and maximizing its corporate value, and in order to promptly respond to the drastically changing business environment.

2. Outline of the Business Reorganization

Zenkaido Corporation (hereinafter "Zenkaido"), a wholly owned subsidiary of PharmaCluster shall merge with Chuo Medical Co., Ltd. ("Chuo Medical" hereinafter), a wholly owned subsidiary of PharmaCluster, on April 1, 2011. In addition, Zenkaido shall change its trade name to Mirai Corporation at the same time.

3. Summary of the absorption type merger

① Schedule of the Merger

February 10, 2011: Conclusion and approval of an absorption type merger agreement

March 23, 2011: Extraordinary shareholders' meeting to approve the absorption type merger agreement (Planned)

April 1, 2011: Date for the merger (Planned)

② Method of the Merger

Consolidation is to be carried out based on an absorption-type merger whereby Zenkaido is the surviving company and Chuo Medical is the absorbed company, and Chuo Medical will be dissolved.

③ Details of the Allocation upon the Merger

There will be no issuance of new shares or an increase in capital stock at the time of the merger due to the fact that the merger is between wholly owned sub-sub-subsidiaries of the Company.

④ Outlines of the Parties involved in the Merger

	Surviving company	Absorbed company
(1) Company name	Zenkaido Corporation	Chuo Medical Co., Ltd.
(2) Business contents	Dispensing pharmacy business	Dispensing pharmacy business
(3) Establishment	March 31, 1981	February 25, 1997
(4) Principal place of business	1st Floor, 13Y Building 3-5 Hejijima, Nishi Ward, Niigata City, Niigata	2-646-107 Hakusanura, Chuo Ward, Niigata City, Niigata
(5) Corporate representative	Takeshi Kurita / President	Takashi Ohi /President
(6) Capital	36 million yen	50 million yen
(7) Number of shares issued	900 shares	1,000 shares
(8) Net sales	5,809 million yen (FY2010)	4,377 million yen (FY2010)
(9) Net assets	1,023 million yen (FY2010)	541 million yen (FY2010)
(10) Total assets	2,357 million yen (FY2010)	1,701 million yen (FY2010)
(11) Fiscal year end	March 31	March 31
(12) Major shareholders and equity holdings	PharmaCluster Co., Ltd. 100.0%	PharmaCluster Co., Ltd. 100.0%

⑤ Effects of the Merger

(1) Company name	Mirai Corporation (A change in company name to Zenkaido Corporation.(Planned))
(2) Business contents	Dispensing pharmacy business
(3) Principal place of business	1st Floor, 13Y Building 3-5 Hejijima, Nishi Ward, Niigata City, Niigata
(4) Corporate representative	Chairman: Takashi Ohi President: Takeshi Kurita
(5) Director	Senior Executive Managing Director: Kazuo Watanabe Executive Managing Director: Hiroshi Nakashima Executive Managing Director: Yukio Watanabe Director: Yoshiro Fujishima Director: Shinobu Hayashi Director: Yosuke Matsumoto Auditor: Mitsuru Kaneuchi
(6) Corporate officer	Corporate officer: Hiro Seiji Corporate officer: Tsuyoshi Takimiya Corporate officer: Akinori Wakao
(7) Capital	36 million yen
(8) Fiscal year end	March 31

4. Impact on business performance

Impacts from the reorganization of the Group's dispensing pharmacy business above on the Company's consolidated operating results are considered insignificant.